Beschreibung:
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Long‐term clinical and molecular remissions in patients with mantle cell lymphoma (MCL) after autologous stem cell transplantation (ASCT) have been evaluated in only a few studies.</jats:p></jats:sec><jats:sec><jats:title>Design and Methods</jats:title><jats:p>Sixty‐five patients with MCL received ASCT (54 first‐line ASCT, 10 second‐line ASCT, and 1 third‐line ASCT). In the case of long‐term remission (≥5 years; <jats:italic>n</jats:italic> = 27), peripheral blood was tested for minimal residual disease (MRD) by t(11;14)‐ and IGH‐PCR at the last follow‐up.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Ten‐year overall survival (OS), progression‐free survival (PFS), and freedom from progression (FFP) after first‐line ASCT were 64%, 52%, and 59% versus after second‐line ASCT 50%, 20%, and 20%, respectively. Five‐year OS, PFS, and FFP for the first‐line cohort were 79%, 63%, and 69%, respectively. Five‐year OS, PFS, and FFP after second‐line ASCT were 60%, 30%, and 30%, respectively. Treatment‐related mortality (3 months after ASCT) was 1.5%. So far 26 patients developed sustained long‐term clinical and molecular complete remissions of up to 19 years following ASCT in first treatment line.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Sustained long‐term clinical and molecular remissions are achievable following ASCT.</jats:p></jats:sec>